---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-072602"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T01:08:10.168241+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma files PCT patent for Alzheimer's treatment using prucalopride and ketamine

## Summary
- PCT patent application filed on August 25, 2023, for methods treating Alzheimer's disease.
- Treatment combines prucalopride (5-HT4 agonist) with ketamine (NMDA antagonist).
- Application seeks international patent protection; no granted status or trial data reported.

## SEC filing metadata
- accession: 0001213900-23-072602
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390023072602/0001213900-23-072602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390023072602/ea184484-8k_silo.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-072602
- JSON: https://secwatch.observer/filing/0001213900-23-072602.json
- Plain text: https://secwatch.observer/filing/0001213900-23-072602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.